How to use the new clinical guidelines “Idiopathic gout”: general principles of symptomatic treatment
https://doi.org/10.14412/19967012-2025-6-98-103
Abstract
Clinical guidelines are a key tool in practical medicine; their primary purpose is to improve the effectiveness of treatment for somatic diseases. The guidelines systematize research data concerning various therapeutic options and regimens, as well as the efficacy and safety of medicinal products, which potentially reduces the risk of complications and improves disease outcomes when accumulated experience is applied rationally. In 2025, the clinical guidelines for idiopathic gout were updated. This article discusses the main approaches to prescribing symptomatic therapy aimed both at alleviating acute arthritis attacks and at preventing subsequent gout flares during the initiation of urate-lowering therapy.
Keywords
gout,
clinical guidelines,
anti-inflammatory therapy,
nonsteroidal anti-inflammatory drugs,
colchicine,
glucocorticoids
Supporting agencies: The article was prepared within the framework of the basic research project “Development of approaches to the phenotyping of autoinflammatory degenerative rheumatic diseases based on a comparative study of biochemical, immunological, and genetic factors associated with the state of bone, cartilage, muscle, and adipose tissues”, №. 125020501433-4
About the Authors
M. N. Chikina
V.A. Nasonova Research Institute of Rheumatology
Russian Federation
Russian Federation
Maria Nikolaevna Chikina
34A, Kashirskoe Shosse, Moscow 115522
M. S. Eliseev
V.A. Nasonova Research Institute of Rheumatology
Russian Federation
Russian Federation
34A, Kashirskoe Shosse, Moscow 115522
Ya. I. Kuzmina
V.A. Nasonova Research Institute of Rheumatology
Russian Federation
Russian Federation
34A, Kashirskoe Shosse, Moscow 115522
References
1. https://cr.minzdrav.gov.ru/view-cr/936_1
2. https://library.mededtech.ru/rest/documents/cr_174/?ysclid=mfw8j4g64l602371301
3. Mandl P, D'Agostino MA, Navarro-Compan V, et al. 2023 EULAR recommendations on imaging in diagnosis and management of crystal-induced arthropathies in clinical practice. Ann Rheum Dis. 2024 May 15;83(6):752759. doi: 10.1136/ard-2023-224771.
4. FitzGerald JD, Dalbeth N, Mikuls T, et al. 2020 American College of Rheumatology Guideline for the Management of Gout. Arthritis Care Res (Hoboken). 2020 Jun; 72(6):744-760. doi: 10.1002/acr.24180.
5. Dalbeth N, Merriman TR, Stamp LK. Gout. Lancet. 2016 Oct 22;388(10055):2039-2052. doi: 10.1016/S0140-6736(16)00346-9.
6. van Durme CM, Wechalekar MD, Landewe RB, et al. Non-steroidal anti-inflammatory drugs for acute gout. Cochrane Database Syst Rev. 2021 Dec 9;12(12):CD010120. doi: 10.1002/14651858.CD010120.pub3.
7. Bradbury F. How important is the role of the physician in the correct use of a drug? An observational cohort study in general practice. Int J Clin Pract Suppl. 2004 Oct:(144):27-32. doi: 10.1111/j.1742-1241.2004.027_e.x.
8. Conforti A, Leone R, Moretti U, et al. Adverse drug reactions related to the use of NSAIDs with a focus on nimesulide: results of spontaneous reporting from a Northern Italian area. Drug Saf. 2001;24(14):1081-90. doi: 10.2165/00002018-200124140-00006.
9. Karateev AE. The Russian experience in the use of nimesulide: clinical trials review. Consilium medicum. 2011;13(9): 89-95. (In Russ.).
10. Joharapurkar A, Kshirsagar S, Patel V, et al. In vivo antidiabetic activity of nimesulide due to inhibition of amino acid transport. Basic Clin Pharmacol Toxicol. 2022 Jan; 130(1):35-43. doi: 10.1111/bcpt.13670.
11. Scalise M, Indiveri C. Repurposing Nimesulide, a Potent Inhibitor of the B0AT1 Subunit of the SARS-CoV-2 Receptor, as a Therapeutic Adjuvant of COVID-19. SLAS Discov. 2020 Dec;25(10):1171-1173. doi: 10.1177/2472555220934421.
12. Kudaeva FM, Eliseev MS, Barskova VG, Nasonova VA. Comparison of the time to analgetic and anti-inflammatory effect in the treatment of gouty arthritis with nimesulide and sodium diclofenac. Terapevticheskii arkhiv. 2007;(5):35-40. (In Russ.).
13. Bernareggi A. Clinical pharmacokinetics of nimesulide. Clin Pharmacokinet. 1998 Oct;35(4):247-74. doi: 10.2165/00003088199835040-00001.
14. Bianchi M, Broggini M. Anti-hyperalgesic effects of nimesulide: studies in rats and humans. Int J Clin Pract Suppl. 2002 Jul: (128):11-9.
15. Rainsford KD. Current status of the therapeutic uses and actions of the preferential cyclo-oxygenase-2 NSAID, nimesulide. Inflammopharmacology. 2006 Aug;14(3-4):120-37. doi: 10.1007/s10787-006-1505-9.
16. Pulkkinen M. Nimesulide in dysmenorrhoea. Drugs. 1993:46 Suppl 1:129-33. doi: 10.2165/00003495-199300461-00028.
17. Finkelstein Y, Aks SE, Hutson JR, et al. Colchicine poisoning: the dark side of an ancient drug. Clin Toxicol (Phila). 2010 Jun; 48(5):407-14. doi: 10.3109/15563650.2010.495348.
18. Wason S, Mount D, Faulkner R. Singledose, open-label study of the differences in pharmacokinetics of colchicine in subjects with renal impairment, including end-stage renal disease. Clin Drug Investig. 2014 Dec; 34(12):845-55. doi: 10.1007/s40261-014-0238-6.
19. Terkeltaub RA, Furst DE, Digiacinto JL, et al. Novel evidence-based colchicine dosereduction algorithm to predict and prevent colchicine toxicity in the presence of cytochrome P450 3A4/P-glycoprotein inhibitors. Arthritis Rheum. 2011 Aug;63(8):2226-37. doi: 10.1002/art.30389.
20. Hansten PD, Tan MS, Horn JR, et al. Colchicine Drug Interaction Errors and Misunderstandings: Recommendations for Improved Evidence-Based Management. Drug Saf. 2023 Mar;46(3):223-242. doi: 10.1007/s40264-022-01265-1.
21. Stamp LK, Horsley C, Karu LT, et al. Colchicine: the good, the bad, the ugly, and how to minimise the risks. Rheumatology (Oxford). 2023 Nov 29:kead625. doi: 10.1093/rheumatology/kead625.
22. McKenzie BJ, Wechalekar MD, Johnston RV, et al. Colchicine for acute gout. Cochrane Database Syst Rev. 2021 Aug 26; 8(8):CD006190. doi: 10.1002/14651858.CD006190.pub3.
23. Zhelyabina OV, Eliseev MS, Glukhova SI, et al. Risk factors for type 2 diabetes mellitus in patients with gout: results from a prospective study. Sovremennaya Revmatologiya = Modern Rheumatology Journal. 2022;16(1): 52-59. (In Russ.). doi: 10.14412/1996-7012-2022-1-52-59.
24. Fedorova AA, Barskova, VG, Yakunina IA, Nasonova VA. Short course of glucocorticoids in patients with protracted and chronic gout arthritis. Part I – predictors of therapy efficacy. Nauchno-Prakticheskaya Revmatologiya. 2008;46(3):62-67. (In Russ.).
25. Schlesinger N, Detry MA, Holland BK, et al. Local ice therapy during bouts of acute gouty arthritis. J Rheumatol. 2002 Feb;29(2): 331-4.
26. Janssens HJ, Janssen M, van de Lisdonk EH, et al. Use of oral prednisolone or naproxen for the treatment of gout arthritis: a double-blind, randomised equivalence trial. Lancet. 2008 May 31;371(9627):1854-60. doi: 10.1016/S0140-6736(08)60799-0.
27. Borstad GC, Bryant LR, Abel MP, et al. Colchicine for prophylaxis of acute flares when initiating allopurinol for chronic gouty arthritis. J Rheumatol. 2004 Dec;31(12): 2429-32.
28. Eliseev MS, Chikina MN, Zhelyabina OV. Colchicine for acute arthritis attacks prevention in patients with gout during urate-lowering therapy (results of a pilot study). Sovremennaya Revmatologiya = Modern Rheumatology Journal. 2021;15(4):50-55. (In Russ.). doi: 10.14412/1996-7012-2021-4-50-55.
29. Chikina MN. Development and application of an algorithm for urate-lowering and prophylactic anti-inflammatory therapy in patients with gout. Diss. cand. med. sci. Moscow: V.A. Nasonova Research Institute of Rheumatology; 2023.108 p.
30. Chikina MN. Prevention of arthritis attacks in the use of urate-lowering therapy in patients with gout. Nauchno-Prakticheskaya Revmatologiya. 2018;56(6):760-766 (In Russ.).
31. Yu J, Qiu Q, Liang L, et al. Prophylaxis of acute flares when initiating febuxostat for chronic gouty arthritis in a real-world clinical setting. Mod Rheumatol. 2018 Mar;28(2): 339-344. doi: 10.1080/14397595.2017.1318467.
Review
For citations:
Chikina MN, Eliseev MS, Kuzmina YI. How to use the new clinical guidelines “Idiopathic gout”: general principles of symptomatic treatment. Sovremennaya Revmatologiya=Modern Rheumatology Journal. 2025;19(6):98-103. (In Russ.) https://doi.org/10.14412/19967012-2025-6-98-103
Views:
50
Email this article 